Clinical trials: Metastatic Prostatic Adenocarcinoma
Prostate Cancer
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
The goal of this clinical research study is learn if adding cabozantinib (also known as XL184) to hormonal therapy can help to control prostate cancer. The safety of this drug will also be studied.
- Trial name
- NCT01630590
- Testing
- Cabozantinib, Androgen Ablation Therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
PET Scan in Treating Patients With Metastatic Prostate Cancer
RATIONALE: New imaging procedures, such as PET scan, may improve the ability to detect new or recurrent prostate cancer.
- Trial name
- NCT00002981
- Testing
- positron emission tomography, fludeoxyglucose F 18, methionine C 11
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Memorial Sloan Kettering Cancer Center